<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323308</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS HB EP 03 CISOVAC</org_study_id>
    <secondary_id>2010-A00511-38</secondary_id>
    <nct_id>NCT02323308</nct_id>
  </id_info>
  <brief_title>Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B Vaccination</brief_title>
  <acronym>ANRSHBEP03</acronym>
  <official_title>Study of Immunological, Virological, Serological Characteristics of HIV+ Patients Harboring Isolated Anti-HBc Profile and Response to Hepatitis B Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of study is to describe the clinical, immunological, serological, virological and
      therapeutic characteristics of HIV+ patients harboring isolated anti-HBc profile and to
      assess the response to vaccination in these patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of immunological, virological and serological characteristics associated to &quot;anti-HBc isolated&quot; profile</measure>
    <time_frame>at Day 0, inclusion visite</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Average titers of anti-HBs Ab</measure>
    <time_frame>at 4 weeks, 28 weeks and 18 months after the first vaccination HBV</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of B-cell phenotype and maturation</measure>
    <time_frame>at baseline and at week 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with HBsAb titers as protective titer&gt;10 IU/L</measure>
    <time_frame>at 4 weeks,28 weeks and 18 month after the first dose HBV vaccin</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of IgG+ memory B cells specific for HBcAg or HBs Ag</measure>
    <time_frame>at baseline and 28 weeks after the first dose HBV vaccin</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Detection of HBV preS2 and S-specific T cells</measure>
    <time_frame>at day 0 and week 28</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">55</enrollment>
  <condition>HIV Infection</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>vaccination</arm_group_label>
    <description>Anti-HBV vaccine injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <arm_group_label>vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HIV infection and presenting with &quot;isolated anti-HBc&quot; profile. HBV
        vaccination is recommended fot these patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV+ adults patients

          -  negative HBsAg

          -  negative a-HBs Ab

          -  positive HBc Ab

          -  without HBV - vaccination

          -  CD4 cell above 200 /mm3

          -  HIV viral load below 50 copies/mL

        Exclusion Criteria:

          -  positive HBs antigenemia in the past

          -  transaminitis above fivefold upper normal limit

          -  PT&lt;50% or Platelet &lt;50 000/mm3

          -  ongoing opportunistic infection

          -  ongoing or recent systemic corticoid or immunomodulatory therapy, splenectomy,
             pregnancy, contra-indication to intramuscular injection, familial history of
             neurological disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lionel Piroth</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU DIJON</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chu Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>December 22, 2014</last_update_submitted>
  <last_update_submitted_qc>December 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

